NM_000051.4:c.5631_5635delCTCGCinsA
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000051.4(ATM):c.5631_5635delCTCGCinsA(p.Phe1877LeufsTer39) variant causes a frameshift, missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000051.4 frameshift, missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.5631_5635delCTCGCinsA | p.Phe1877LeufsTer39 | frameshift_variant, missense_variant | Exon 37 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:3
The observed frameshift variant c.5631_5635delCTCGCinsAp.Phe1877LeufsTer39 in the ATM gene has been reported previously in compound heterozygous state in an individual with ataxia-telangiectasia Babaei M, et al., 2005. This variant is absent in the gnomAD Exomes. This variant causes a frameshift starting with codon Phenylalanine 1878, changes this amino acid to Leucine residue, and creates a premature Stop codon at position 39 of the new reading frame, denoted p.Phe1877LeufsTer39. It is submitted to ClinVar as Pathogenic/Likely pathogenic. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants have been previously reported to be disease causing. 5. However study on multiple affected individuals and functional studies on the pathogenicity of the variant is unavailable. For these reasons, this variant has been classified as Likely Pathogenic. -
This variant was determined to be likely pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. -
This sequence change creates a premature translational stop signal (p.Phe1877Leufs*39) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia (PMID: 15843990). This variant is also known as c.5631_5635delCTCGC+5639_5640insA. ClinVar contains an entry for this variant (Variation ID: 302252). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.5631_5635delCTCGCinsA pathogenic mutation, located in coding exon 36 of the ATM gene, results from the deletion of 5 nucleotides and insertion of one nucleotide causing a translational frameshift with a predicted alternate stop codon (p.F1877Lfs*39). This alteration, described as c.5631_5635delCTCGC+5639_5640insA, has been reported in two individuals from a cohort of Iranian ataxia-telangiectasia patients (Babaei M et al, Hum. Genet. 2005 Jul; 117(2-3):101-6) as well as in three individuals from an Indian ataxia-telangiectasia patient cohort (Rawat A et al, Sci Rep. 2022 03;12(1):4036). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
This variant deletes 5 nucleotides and inserts 1 new nucleotide in exon 37 of the ATM gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in the compound heterozygous state with an additional pathogenic ATM variant in individuals affected with ataxia-telangiectasia (PMID: 15843990, 35729272). This variant has also been reported in individuals affected with triple negative breast cancer (DOI: 10.1101/2022.05.31.22275080). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Familial cancer of breast Pathogenic:2
- -
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:1
The frameshift variant c.5631_5635delinsA (p.Phe1877LeufsTer39) in ATM has been reported in heterozygous state in individuals affected with ataxiatelangiectasia (Babaei M et al.). The p.Phe1877LeufsTer39 variant is novel in the gnomAD Exomes database. It has been submitted to ClinVar as Pathogenic and Likely Pathogenic. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Loss-offunction variants in ATM are known to be pathogenic (Huang Y et al.). For these reasons, this variant has been classified as Pathogenic. -
ATM-related cancer predisposition Pathogenic:1
- -
not provided Pathogenic:1
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 15843990) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at